Zydus Cadila, a Gujarat based pharmaceutical is conducting trials on children in the age group of 12 to 18 years. Once the data regarding the efficacy of the vaccine is submitted, the Subject Expert Committee (SEC) will review the data.

ZyCoV-D, the vaccine indigenously manufactured by Zydus Cadila is likely to get the approval of DCGA in a few days.

The ZyCoV-D vaccine developed for children above 12 years is a three-dose, intradermal vaccine, and is needle-free, also leading to a significant reduction in any kind of side effects. Interim analysis has shown it to be 66.6 per cent effective for symptomatic RT-PCR positive cases.

The SEC is expected to meet this week and review the data. If the data is found to be satisfactory, Drugs Controller General of India (DCGI) may grant its approval within few days to Zydus Cadila for emergency use.  

(with inputs from india.com)